1197 related articles for article (PubMed ID: 26587698)
1. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
2. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
[TBL] [Abstract][Full Text] [Related]
3. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.
Yamada S; Fujii T; Hirakawa A; Takami H; Suenaga M; Hayashi M; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
Pancreas; 2018 Sep; 47(8):974-979. PubMed ID: 30028445
[TBL] [Abstract][Full Text] [Related]
5. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
6. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry.
Worni M; Akushevich I; Gloor B; Scarborough J; Chino JP; Jacobs DO; Hahn SM; Clary BM; Pietrobon R; Shah A
Ann Surg Oncol; 2012 Apr; 19(4):1316-23. PubMed ID: 22002799
[TBL] [Abstract][Full Text] [Related]
8. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
[TBL] [Abstract][Full Text] [Related]
9. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
[TBL] [Abstract][Full Text] [Related]
10. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
[TBL] [Abstract][Full Text] [Related]
11. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.
Turrini O; Waters JA; Schnelldorfer T; Lillemoe KD; Yiannoutsos CT; Farnell MB; Sarr MG; Schmidt CM
HPB (Oxford); 2010 Sep; 12(7):447-55. PubMed ID: 20815853
[TBL] [Abstract][Full Text] [Related]
12. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
14. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma.
Shimada K; Sakamoto Y; Sano T; Kosuge T; Hiraoka N
Pancreas; 2006 Apr; 32(3):281-7. PubMed ID: 16628084
[TBL] [Abstract][Full Text] [Related]
15. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
16. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.
Wasif N; Bentrem DJ; Farrell JJ; Ko CY; Hines OJ; Reber HA; Tomlinson JS
Cancer; 2010 Jul; 116(14):3369-77. PubMed ID: 20564064
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.
Swartz MJ; Hsu CC; Pawlik TM; Winter J; Hruban RH; Guler M; Schulick RD; Cameron JL; Laheru DA; Wolfgang CL; Herman JM
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):839-44. PubMed ID: 19647950
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.
Tanaka T; Kuroki T; Adachi T; Ono S; Hirabaru M; Soyama A; Kitasato A; Takatsuki M; Hayashi T; Eguchi S
Pancreas; 2013 Apr; 42(3):488-93. PubMed ID: 23146920
[TBL] [Abstract][Full Text] [Related]
19. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.
Wada K; Kozarek RA; Traverso LW
Am J Surg; 2005 May; 189(5):632-6; discussion 637. PubMed ID: 15862510
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
Lucocq J; Hawkyard J; Haugk B; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; Van Laarhoven S; Robertson F; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Søreide K; Pandanaboyana S
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38659247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
